The Global Health Body Sounds Concern Over Critical Scarcity of Weight-Loss Injections

Fewer than a tenth of patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, warns the World Health Organization as it releases its initial advice on the therapies.

Considering more than one billion individuals worldwide currently classified as obese, it is advocating for increased and just availability to GLP-1 medication.

Per forecasts, over two billion could be obese by 2030 without intervention.

"Our latest guidelines affirms that obesity is a long-term condition that can be managed with thorough and continuous care," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and supply-chain constraints are key hurdles to widespread access to the injections that can aid individuals in losing substantial body mass, says the agency.

Skinny Jab Scarcity

Even in the current best projected outlook, the supply of these medications might only reach around 100 million people – less than 10% of eligible patients, according to the WHO.

The advice urges nations and manufacturers to expand access, by strategies including licensing agreements.

A patent on a key compound – the core component of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.

How Obesity Injections Operate

GLP-1 drugs replicate a natural hormone to slow digestion, curb appetite and boost satiety so people reduce food intake.

People commonly see weight reduction after several weeks of starting on the once-weekly jabs.

Evidence indicates patients may regain a significant portion within a year of discontinuing the treatment, when their usual hunger resume.

Being carrying excess weight increases your likelihood for experiencing diseases, including type 2 diabetes, heart disease, stroke, and specific malignancies.

Obesity concerns people in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.